Enovis (NYSE:ENOV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Enovis (NYSE:ENOV) posted its earnings results on Thursday. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.85 by $0.05, FiscalAI reports. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.79 earnings per share. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

• Second-quarter organic sales grew 5%, led by 6% growth in Recon and 3% in PNR. U.S. Recon hips and knees and extremities each grew 8% in the first half, while Nebula, ARG, and the full commercial launch of ARVIS are gaining traction.
• Adjusted gross margin improved 120 basis points on an underlying basis, and adjusted EBITDA margin rose 70 basis points to 17.9%. Management cited favorable product mix, productivity, and Lima integration synergies, and expects continued multi-year margin expansion.
• Free cash flow improved by $27 million year over year to $31 million in the quarter, bringing first-half cash flow slightly positive. The company reaffirmed its target of greater than 25% free-cash-flow conversion for 2026 and aims to reduce leverage below 3x.
• Enovis reaffirmed its 2026 guidance but expects a seasonally weaker-than-usual third quarter because of softer Western European markets and Middle East-related disruption, followed by sales acceleration in the fourth quarter.
• Inflationary pressure from raw materials, freight, distribution, and the Middle East conflict reduced second-quarter results by $2 million and is expected to total a $10 million full-year impact. Management said passing through additional costs remains difficult, particularly in PNR, because of competitive and market pressures.

Enovis Trading Up 1.4%

NYSE ENOV traded up $0.38 during trading on Friday, hitting $26.68. 2,058,436 shares of the company’s stock traded hands, compared to its average volume of 1,111,529. The stock has a fifty day moving average of $24.62 and a two-hundred day moving average of $23.97. Enovis has a 12-month low of $19.14 and a 12-month high of $34.28. The firm has a market cap of $1.54 billion, a P/E ratio of -1.39 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.05.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 4,200 shares of company stock valued at $92,084 in the last quarter. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enovis

A number of large investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its holdings in Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after buying an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares during the last quarter. Empowered Funds LLC increased its position in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Finally, Amundi increased its position in shares of Enovis by 24,405.0% in the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ENOV. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Enovis in a research note on Friday. BTIG Research lifted their target price on shares of Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.